Guided Therapeutics Inc (GTHP) stock
GTHPOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
$0.16−0.03 (-15.79%)
Close on Oct 19, 2026Market cap $15.45MP/E –Yield –
Guided Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Guided Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$1.50M. For fiscal 2025 it was -$1.07M. The highest annual figure on record is -$806.00K in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.07M | – |
| FY2024 | Dec 31, 2024 | -$1.12M | – |
| FY2023 | Dec 31, 2023 | -$1.75M | – |
| FY2022 | Dec 31, 2022 | -$1.48M | – |
| FY2021 | Dec 31, 2021 | -$1.59M | – |
| FY2020 | Dec 31, 2020 | -$1.88M | – |
| FY2019 | Dec 31, 2019 | -$806.00K | – |
| FY2018 | Dec 31, 2018 | -$1.37M | – |
| FY2017 | Dec 31, 2017 | -$1.14M | – |
| FY2016 | Dec 31, 2016 | -$1.80M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$319.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$617.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$291.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$277.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$169.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$331.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$332.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$473.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$214.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$100.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$336.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$473.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$438.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$499.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$339.00K | -313.2% |
| Q3 FY2022 | Sep 30, 2022 | -$612.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$349.00K | – |
| Q1 FY2022 | Mar 31, 2022 | -$179.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $159.00K | – |
| Q3 FY2021 | Sep 30, 2021 | -$739.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$692.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$320.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$331.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$606.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$408.00K | – |
| Q1 FY2020 | Mar 31, 2020 | -$530.00K | – |
| Q4 FY2019 | Dec 31, 2019 | -$204.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$228.00K | – |
| Q2 FY2019 | Jun 30, 2019 | -$188.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$186.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$311.00K | – |
| Q3 FY2018 | Sep 30, 2018 | -$417.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$242.00K | -286.2% |
| Q1 FY2018 | Mar 31, 2018 | -$395.00K | – |
| Q4 FY2017 | Dec 31, 2017 | -$663.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$204.00K | – |
| Q2 FY2017 | Jun 30, 2017 | $130.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$407.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$197.00K | – |
See a number that looks wrong?